Table 3. Adjusted HRs of Death After Omicron Infection for Treatments by Subgroup.

Variable	Nirmatrelvir		Molnupiravir
	Patients, No. treated/total No.	HR (95% CI)	Patients, No. treated/total No.	HR (95% CI)
Age, y
12-64	11 291/37 087	0.12 (0.04-0.34)	2085/26 579	0.13 (0.04-0.43)
≥65	11 303/25 237	0.16 (0.11-0.24)	3226/18 083	0.24 (0.16-0.37)
Race and ethnicity
Non-Hispanic White	18 571/46 113	0.15 (0.10-0.23)	4499/31 878	0.23 (0.15-0.34)
All others	4023/16 211	0.18 (0.07-0.50)	812/12 784	0.23 (0.07-0.73)
Vaccine boosters
Yes	16 966/36 761	0.13 (0.08-0.21)	4162/24 174	0.21 (0.13-0.34)
No	5628/25 563	0.22 (0.12-0.40)	1149/20 488	0.27 (0.13-0.57)
Previous infection
Yes	1816/6947	0.32 (0.09-1.08)	444/5467	0.47 (0.17-1.35)
No	20 778/55 377	0.15 (0.10-0.22)	4867/39 195	0.21 (0.14-0.32)
Respiratory disorders
Yes	3994/11 623	0.07 (0.03-0.20)	1242/8938	0.24 (0.13-0.46)
No	18 600/50 701	0.19 (0.13-0.29)	4069/35 724	0.23 (0.14-0.37)
Immunocompromised disorders
Yes	1339/3627	0.26 (0.15-0.45)	960/3849	0.22 (0.13-0.37)
No	21 255/58 697	0.11 (0.06-0.19)	4351/40 813	0.21 (0.12-0.38)
Cardiovascular system disorders
Yes	9472/24 187	0.18 (0.12-0.27)	3045/18 708	0.21 (0.14-0.33)
No	13 122/38 137	0.09 (0.03-0.26)	2266/25 954	0.37 (0.15-0.92)
Diabetes
Yes	3263/8579	0.20 (0.10-0.38)	1215/7080	0.19 (0.10-0.37)
No	19 331/53 745	0.14 (0.09-0.23)	4096/37 582	0.26 (0.16-0.41)
Obesity
Yes	3255/8911	0.10 (0.03-0.33)	901/6622	0.23 (0.10-0.53)
No	19 339/53 413	0.17 (0.11-0.25)	4410/38 040	0.23 (0.15-0.36)
Other nonrespiratory disorders
Yes	10 200/28 240	0.16 (0.11-0.25)	3143/21 713	0.21 (0.14-0.32)
No	12 394/34 084	0.13 (0.05-0.36)	2168/22 949	0.39 (0.14-1.10)
Date of COVID-19 diagnosis
April 1 to June 21, 2022	3762/13 349	0.08 (0.03-0.26)	649/10 023	0.27 (0.11-0.68)
June 22 to November 30, 2022	13 190/35 231	0.16 (0.10-0.26)	2778/24 603	0.22 (0.13-0.38)
December 1 to February 20, 2023	5642/13 744	0.20 (0.10-0.43)	1884/10 036	0.21 (0.10-0.46)

Abbreviation: HR, hazard ratio.